KMDA Kamada Ltd.

-0.04  -1%
Previous Close 4.72
Open 4.68
Price To Book 2.01
Market Cap 188552695
Shares 40,267,527
Volume 4,878
Short Ratio
Av. Daily Volume 9,791

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 initiated April 2016. Interim analysis 2H 2018. Top-line data due 2H 2019.
Alpha-1 antitrypsin (AAT)
Prevention of lung transplant rejection
Approval announced August 25, 2017.
Prophylaxis of rabies disease
Top-line data released August 30, 2016. Primary endpoint met. Company noted April 23, 2018 safety concerns by FDA. Initiation of Phase 3 trial uncertain.
Inhaled formulation of AAT
AATD - Alpha-1 Antitrypsin deficiency
Phase 2 data released November 3, 2017. No significant treatment effect noted overall.
Alpha-1 Antitrypsin (AAT)
Pediatric patients newly diagnosed with type 1 diabetes
Phase 2 data due 2H 2019.
Alpha-1 antitrypsin (AAT)
Graft Versus Host Disease (GvHD)